Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bio_kruncher who wrote (21334)	9/18/2006 8:37:02 PM
From: Biomaven	Read Replies (1) of 52153

FWIW, NVS is the only pharma I own. Bought it about a year or so ago in the mid 40's, but in no great size. They are certainly spreading their money around by partnering vigorously, some might even say recklessly. I sat next to their US director of R&D on a train ride between NYC and Boston a year or two back - he had a bunch of charts he showed me for an internal presentation he was preparing. The charts showed how much more productive NVS had been compared with other big pharma in terms of number of succesful NDA's over the last several years. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next